Bevacizumab-Induced Hypertension Indicative of Better Survival in Glioblastoma

Share this content:

the Cancer Therapy Advisor take:

When compared to normotensive patients with recurrent glioblastoma (GBM), individuals who developed bevacizumab-induced hypertension experienced increased progression-free survival (PFS) and overall survival (OS), according to an article published online in Cancer.

In this study, 82 patients with recurrent GBM were identified as being treated using bevacizumab within the Emory Healthcare system from 2007 through 2012.  Of the 82 patients, 30 developed bevacizumab-induced hypertension. The patients were categorized as normotensive or hypertensive based on if their hypertension was drug-induced.

Results showed that the median follow-up period was 19.7 months and the median time to the development of drug-induced hypertension was 21 days.

Furthermore, the median PFS was 2.5 months (95% CI: 1.6, 3.0) for the normotensive group and 6.7 months (95% CI: 4.6, 10.0) for the hypertensive group (PP<0.001).

The study suggests that drug-induced hypertension resulting from treatment with bevacizumab may be a physiologic marker of outcome in individuals with recurrent GBM.

The patients with bevacizumab-induced hypertension displayed greater PFS and OS compared with normotensive patients.

CNS relapse in peripheral T-cell lymphoma occurs at a frequency similar to B-cell lymphomas.
Glioblastoma patients who developed bevacizumab-induced hypertension experienced increased survival.
Bevacizumab-induced hypertension is a well-documented side effect, and some reports have suggested this occurrence to be related to treatment outcome in other cancers.
READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters